Ignite Creation Date:
2025-12-24 @ 9:19 PM
Ignite Modification Date:
2025-12-29 @ 11:25 AM
Study NCT ID:
NCT04868604
Status:
RECRUITING
Last Update Posted:
2025-12-17
First Post:
2021-04-15
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)
Sponsor:
Clarity Pharmaceuticals Ltd
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-08-11
Start Date Type:
ACTUAL
Primary Completion Date:
2026-09
Primary Completion Date Type:
ESTIMATED
Completion Date:
2026-09
Completion Date Type:
ESTIMATED
First Submit Date:
2021-04-15
First Submit QC Date:
None
Study First Post Date:
2021-05-03
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-12-16
Last Update Post Date:
2025-12-17
Last Update Post Date Type:
ESTIMATED